15

CLAIMS:

- A naturally occurring low molecular weight adenosine A3 receptor agonist (LMW-A3RAg).
- 2. The LMW-A3RAg of Claim 1, obtainable from a vertebrate tissue or a
- 5 vertebrate-derived cell by extraction in a liquid medium.
 - The LMW-A3RAg of Claim 2, obtainable from muscle tissue.
 - The LMW-A3RAg of Claim 1, obtainable from medium conditioned by vertebrate source cells.
 - 5. The LMW-A3RAg of Claim 4, wherein said source cells are muscle cells.
- The LMW-A3RAg of Claim 4, wherein said source cells are white blood cells.
 - The LMW-A3RAg of Claim 1, which is resistant to degradation by adenosine deaminase.
 - The LMW-A3RAg of Claim 1, having the following characteristics:
 - it is obtainable from animal-derived tissue or cells;
 - (ii) it filters through a filter with a maximal molecular weight cut-off of about 3,000 Daltons;
 - (iii) it is water soluble, heat stable, non-proteinaceous and resistant to adenosine dearninase activity.
- A synthetic molecule having the same chemical structure as the agonist of Claim 1
 - 10. A pharmaceutical composition comprising as an active ingredient, a therapeutically effective amount of at least one naturally occurring LMW-A3RAg and a pharmaceutically acceptable excipient.
- 25 11. A pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of the molecule of Claim 9.
 - The pharmaceutical composition of Claim 10 or 11, formulated in any form suitable for oral administration.

- 13. A method for a therapeutic treatment comprising administering to a subject in need an effective amount of a naturally occurring A3RAg for achieving a therapeutic effect, the therapeutic effect comprises inhibition of adenylate cyclase in target cells.
- 5 14. The method of Claim 13, wherein said LMW-A3RAg is administered in combination with an additional therapeutic treatment.
 - 15. The method of Claim 13 or 14, wherein said LMW-A3RAg is administered orally to the subject in need.
- 16. A method for a therapeutic treatment comprising administering to a subject
 10 in need an effective amount of a molecule according to Claim 9.